Tenderwize
Zurück zur Suche

Open house discount agreements for Rilpivirin depot injection suspension, ATC J05AG05

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline Apr 03, 2028 · 584 days left·Open·Supplies·Framework
Registrieren zum SpeichernOpen documents
Structured notice only
Originaltitel der Bekanntmachung

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Rilpivirin in der Darreichungsform Depot-Injektionssuspension, ATC J05AG05

60/100

Opportunity Score

PromisingLow complexity
SuppliesFrameworkOpen
Warum diese Bewertung?

Chance

60 / 100

Komplexität

20 / 100

Risikofaktoren

No estimated contract value or maximum framework amount is provided. It is unclear what volume of business these discou...

The open-house agreements may automatically terminate if a national or regional discount contract for the same product...

Tiefe Portfolioanalyse

Tiefe Analyse der Unternehmenspassung

Verwendet:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Überblick

Strong opportunity

Wichtige Fakten

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until May 2028
  • Non-exclusive discount agreements for the pharmaceutical product Rilpivirin (ATC J05AG05) in depot injection suspension form.
  • Contracts are offered to all eligible pharmaceutical companies without competition.
Vollständige Zusammenfassung anzeigen

This is an open-house model (not a standard procurement procedure) for non-exclusive discount agreements for the pharmaceutical product Rilpivirin in depot injection suspension form (ATC J05AG05). The buyer, AOK Bayern, offers identical, non-negotiable contracts to all interested pharmaceutical companies that meet the eligibility criteria. The early possible start date is 01.06.2026, all contracts end 31.05.2028. Contract conclusion is possible anytime until 03.04.2028. Termination is possible with one month's notice. There is no competition or award selection; any eligible company can join. The estimated value is not provided.

Risiken

No estimated contract value or maximum framework amount is provided. It is unclear what volume of business these discou...

The open-house agreements may automatically terminate if a national or regional discount contract for the same product...

Analyse kann unvollständig sein

Nur ein Teil der Vergabeunterlagen wurde analysiert. Weitere Anforderungen, Zertifikate oder Einreichungsdokumente können in den übrigen Unterlagen enthalten sein.

Wichtige Anforderungen

Eligibility

  • Only pharmaceutical companies are eligible as potential contracting partners.
  • Eligibility is proven by a signed self-declaration of reliability (downloadable from the procurement documents).

Administrative

  • Submission must include the signed contract, the signed annex "Determination of the contract medicines", and the signed self-declaration.

Anforderungen können unvollständig sein.

Auftraggeber

Ort

München, DEU

Website

www.aok.de

Auftraggeberprofil

Profil öffnen

Kennung

DE811695320

Tätigkeit

Health

Lose (1)

LOT-0001

Open house discount agreements for Rilpivirin depot injection suspension, ATC J05AG05

Non-exclusive discount agreements for the active substance Rilpivirin in depot injection suspension form. Contracts are identical for all participants. The contract period is from 01.06.2026 to 31.05.2028. Submission deadlines are rolling: to get a contract start on the next month's first day, complete documents must be submitted by the 3rd of the previous month.

SuppliesFrameworkEU fundedElectronic submission

Ort

DE212, Germany

Dauer

May 2026 - May 2028

Kategorie

Pharmaceutical products

Frist

Deadline Apr 03, 2028

Vergabedetails

Veröffentlichungsdatum
14 Apr 2026
Sprachen
German

Referenzmetadaten

Rechtsgrundlage
32014L0024

Referenz-IDs

Ausschreibungs-ID
255478-2026

Dokumente (2)

Vergabedokument 1Einreichungsportal 1

Ähnliche Ausschreibungen

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30